Status:
UNKNOWN
Prognosis and Targeted Therapy Related Molecular Screening Program for Patients of Breast Cancer in China
Lead Sponsor:
Peking University Cancer Hospital & Institute
Collaborating Sponsors:
Predicine (Shanghai) Medical Technology Co., Ltd.
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-80 years
Brief Summary
The anticipated objectives of this study are: 1) to understand the pathogenesis and molecular typing of breast cancer patients in China (mainly HER2 overexpression, triple negative and hormone recepto...
Eligibility Criteria
Inclusion
- patients with first treated or recurrent metastatic breast cancer, according to RECIST version 1.1 standard, confirmed by CT or MRI, have at least one measurable lesion.
- HER2 positive or triple negative patients; (IHC++, fish amplification)
- Patients with anti-HER2 treatment as first-line or not, and patients with HER2 positive can be treated with adjuvant therapy containing trastuzumab.
Exclusion
- \-
Key Trial Info
Start Date :
July 20 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2019
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03792529
Start Date
July 20 2017
End Date
June 1 2019
Last Update
January 3 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142